Pasar al contenido principal

THE FANCONI ANEMIA/BRCA PATHWAY: GENOMIC MEDICINE AND ADVANCED THERAPIES

PID2021-122411OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario INSTITUT DE RECERCA DE L HOSPITAL DE LA SANTA CREU I SANT PAU

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Persico, Ilaria
  • Cavero, Debora|||0000-0002-8912-1890
  • de la Cal, Aurora
  • Río, Paula
  • Navarro Ordóñez, Susana|||0000-0002-0764-5384
  • Casado, José A.|||0000-0003-2479-1508
  • Bailador, Almudena
  • Sanchez de la Fuente, Antonio
  • López de Heredia, Miguel|||0000-0003-2826-9565
  • Almazán Castro, Francisco|||0000-0001-6894-9376
  • Antelo, Maria Luisa|||0000-0002-4280-4432
  • Argilés, Bienvenida
  • Badell Serra, Isabel|||0000-0001-6546-2175
  • Baragaño, Marta|||0000-0002-4041-2021
  • Beléndez, Cristina|||0000-0002-6019-6557
  • Bermúdez, Mar
  • Bernués, Marta
  • Buedo Rubio, María Isabel|||0000-0002-2967-1647
  • Carrasco, Estela|||0000-0003-1964-7675
  • Català, Albert|||0000-0003-0133-1752
  • Costa, Dolors|||0000-0002-8276-3292
  • Cuesta, Isabel
  • Fernandez-Delgado, Rafael
  • Fernandez-Teijeiro, Ana|||0000-0002-2359-9330
  • Figuera, Ángela
  • García, Marta|||0000-0001-5155-4730
  • Gondra, Ainhoa
  • González Cruz, Macarena
  • González Muñiz, Soledad
  • Hernandez-Rodriguez, Inés|||0000-0003-2550-9041
  • Ibañez, Fátima
  • Kelleher, Nicholas John
  • Lendínez, Francisco
  • Lopez Rodriguez, Monica|||0000-0001-8134-9682
  • López-Almaraz, Ricardo
  • Marchante, Inmaculada
  • Mendoza, Carmen
  • Nieto, José
  • Ojeda, Emilio
  • Payán-Pernía, Salvador|||0000-0002-4288-7362
  • Peláez, Irene
  • Pérez de Soto, Inmaculada
  • Portugal, Raquel|||0000-0002-7144-9409
  • Ramos-Arroyo, María A.|||0000-0002-7171-9202
  • Regueiro, Alexandra
  • Rodríguez, Ana
  • Rosell, Jordi
  • Saez, Raquel
  • Sánchez, José
  • Sánchez, Martha
  • Senent, Maria Leonor
  • Tapia, María
  • Trujillo-Quintero, Juan Pablo|||0000-0001-5901-9388
  • Vagace Valero, José Manuel|||0000-0001-8751-4319
  • Verdú-Amorós, Jaime|||0000-0002-0900-0889
  • Verdugo, Victória
  • Vidales, Isabel
  • Villarreal, Jasson
  • Díaz de Heredia, Cristina|||0000-0001-8086-296X
  • Sevilla, Julián|||0000-0002-6852-1860
  • Bueren, Juan|||0000-0002-3228-7013
  • Surralles, Jordi|||0000-0002-4041-7519
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later-onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG, with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting protein-protein interactions in drug discovery, Modulators approved or in clinical trials for cancer treatment

  • Camps-Fajol, Cristina
  • Cavero, Debora|||0000-0002-8912-1890
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2-4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ending diagnostic odyssey by reanalysis of whole exome sequencing data, reclassification of suspected Fanconi anemia cases to dyskeratosis congenita and Diamond-Blackfan anemia

  • Tejero Laguna, Eudald|||0000-0002-7536-4322
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Surralles, Jordi|||0000-0002-4041-7519
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
Initial Whole Exome Sequencing frequently fails to resolve rare disease cases. Bioinformatic reanalysis of existing genomic data utilizes advancing knowledge to enhance diagnosis without additional testing. This study investigated six patients with clinical features consistent with Fanconi Anemia but negative chromosomal breakage tests, whose initial genetic analyses were inconclusive. Whole Exome Sequencing data from these patients (collected 2005-2009) underwent comprehensive reanalysis, including single nucleotide variants, insertions/deletions, and copy number variants across genes beyond those typically associated with Fanconi Anemia. Telomere length was assessed via monochrome multiplex quantitative PCR. Reanalysis identified clinically significant variants in two patients (33.3% yield): one harboured a heterozygous pathogenic loss-of-function variant in the Diamond-Blackfan anemia gene RPL5, while the second exhibited compound heterozygous variants in the TERT gene, indicative of dyskeratosis congenita. This study underscores the clinical value of reanalyzing existing genomic data in unresolved suspected genetic disorders, even when phenotype-specific assays are negative. The 33.3% diagnostic yield aligns with gains from larger reanalysis studies (10-25%). Systematic reassessment after sufficient time (24 + months) for genomic advancements offers a cost-effective diagnostic approach for long-undiagnosed cases, highlighting the dynamic nature of genomic interpretation as gene-disease understanding evolves. The online version contains supplementary material available at 10.1186/s13023-025-03928-5.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

  • Ramírez, María José
  • Pujol, Roser
  • Minguillón, Jordi
  • Bogliolo, Massimo
  • Persico, Ilaria
  • Cavero, Débora
  • Cal, Aurora de la
  • Río, Paula
  • Rodríguez-Navarro, Susana
  • Casado, José Antonio
  • Bailador, Almudena
  • Fuente, Antonio Sánchez de la
  • Heredia, Miguel López de
  • Almazán, Francisco
  • Antelo, M. Luisa
  • Argilés, Bienvenida
  • Badell, Isabel
  • Baragaño, Marta
  • Beléndez, Cristina
  • Bermúdez, Mar
  • Bernués, Marta
  • Buedo, María Isabel
  • Carrasco, Estela
  • Català, Albert
  • Costa, Dolors
  • Cuesta, Isabel
  • Fernandez-Delgado, Rafael
  • Fernández-Teijeiro, Ana
  • Figuera, Ángela
  • García, Marta
  • Gondra, Ainhoa
  • González, Macarena
  • Muñiz, Soledad González
  • Hernández-Rodríguez, Inés
  • Ibáñez, Fátima
  • Kelleher, Nicholas John
  • Lendínez, Francisco
  • López, Mónica
  • López-Almaraz, Ricardo
  • Marchante, Inmaculada
  • Mendoza, Carmen
  • Nieto, José
  • Ojeda, Emilio
  • Payán-Pernía, Salvador
  • Peláez, Irene
  • Soto, Inmaculada Pérez de
  • Portugal, Raquel
  • Ramos-Arroyo, María A.
  • Regueiro, Alexandra
  • Rodríguez, Ana
  • Rosell, Jordi
  • Sáez, Raquel
  • Sánchez, José
  • Sánchez, Martha
  • Senent, Leonor
  • Tapia, María
  • Trujillo-Quintero, Juan Pablo
  • Vagace, José Manuel
  • Verdú-Amorós, Jaime
  • Verdugo, Victória
  • Vidales, Isabel
  • Villarreal, Jasson
  • Díaz de Heredia, Cristina
  • Sevilla, Julián
  • Bueren, Juan Antonio
  • Surrallés, Jordi
Fanconi anemia (FA) is a rare genetic disease characterized by high phenotypic and genotypic heterogeneity, and extreme chromosome fragility. To better understand the natural history of FA, identify genetic risk and prognostic factors, and develop novel therapeutic strategies, the Spanish Registry of Patients with FA collects data on clinical features, chromosome fragility, genetic subtypes, and DNA sequencing with informed consent of participating individuals. In this article, we describe the clinical evolution of 227 patients followed up for up to 30 years, for whom our data indicate a cumulative cancer incidence of 86% by age 50. We found that patients with lower chromosome fragility had a milder malformation spectrum and better outcomes in terms of later-onset hematologic impairment, less severe bone marrow failure, and lower cancer risk. We also found that outcomes were better for patients with mutations leading to mutant FANCA protein expression (genetic hypomorphism) than for patients lacking this protein. Likewise, prognosis was consistently better for patients with biallelic mutations in FANCD2 (mainly hypomorphic mutations) than for patients with biallelic mutations in FANCA and FANCG, with the lack of the mutant protein in patients with biallelic mutations in FANCG contributing to their poorer outcomes. Our results regarding the clinical impact of chromosome fragility and genetic hypomorphism suggest that mutant FA proteins retain residual activity. This finding should encourage the development of novel therapeutic strategies aimed at partially or fully enhancing mutant FA function, thereby preventing or delaying bone marrow failure and cancer in patients with FA. Clinical Trial Registration number: NCT06490510., This study has been funded by Ministerio de Ciencia e Innovación through the project “The Fanconi anemia/BRCA pathway: Genomic medicine and advanced therapies” (FABRAT, PID2021-122411OB-I00/AEI/10.13039/501100011033/FEDER, UE); the Instituto de Salud Carlos III (ISCIII) and fondos Next Generation EU: Plan de Recuperación, trasformación y resiliencia de la UE through the project “Reposicionamiento de afatinib para HNSCC en pacientes con anemia de Fanconi” (ICI22/00076); the ICREA-Academia program, Fundació Institut Català de Recerca i Estudis Avançats 2018; SGR-Cat 2021 (AGAUR) through the project “Genomic medicine and rare diseases group” (2021-SGR-00835, 2023–2025). CIBERER is an initiative of the Instituto de Salud Carlos III, Spain., Peer reviewed